Press & Media

For Journalists and Researchers

phrma.in is an independent research publication built on official government trade statistics and public company filings. Every number on this site traces to a named source. This page provides quick-reference statistics, story leads, and attribution guidance for media use.

176 Country Profiles

Bilateral pharmaceutical trade data for every country India exports to, with trend charts, composition breakdowns, and source attribution. Based on DGCIS (India) trade data, FY2015–FY2026.

56 Company Profiles

31 Indian pharmaceutical “Champions” and 25 Global Innovators with India operations. Revenue data from published annual reports and stock exchange filings.

Patent & Innovation Data

187,353 pharmaceutical patent filings in India since 1987, charted by company. Source: Indian Patent Office (IPAIRS database).

Policy & Affordability

Drug pricing architecture (DPCO, NLEM), humanitarian aid data (MEA), and evidence-checked policy analysis with explicit source triangulation.

Key Statistics for Citation

These are the most frequently cited figures from phrma.in, each with its primary source. All are suitable for publication with attribution.

Statistic	Figure	Source
India pharma exports, FY2025–26	$31+ billion	DGCIS India
Export growth, FY15–FY26	+124% ($14B → $31B)	DGCIS India
Countries served	200+	DGCIS India
US FDA-registered facilities	1,030+	US FDA
Patent filings, 2024	18,668	Indian Patent Office (IPAIRS)
Patent filings growth, 2014–2024	+161%	Indian Patent Office (IPAIRS)
Global generics supply (by volume)	20%	IBEF, GaBI Online
Global vaccine supply	60%	IBEF, Invest India
Domestic market size (2025)	~$55 billion	Bain & Company / IBEF
Global market rank (by volume)	3rd largest	Department of Pharmaceuticals
Humanitarian medicine shipments (since 2023)	56 countries, 1,388 MT	Ministry of External Affairs
Essential medicines under price control	384 drugs (NLEM 2022)	NPPA / PIB

Story Leads

Each of these narratives is fully developed on phrma.in with data, charts, and source attribution.

India’s Quiet Diplomacy: Medicine as Foreign Policy

Since 2023, India has shipped essential medicines, vaccines, and medical equipment to 56 countries through the Ministry of External Affairs — from Nauru to Ukraine, from dialysis machines to BHISHM mobile hospitals. This is separate from commercial trade and is not included in export figures. The full dataset of 84 shipments is sourced from MEA documentation.

Read: India’s Helping Hand →

From $84,000 to $100: How India Broke the Drug Pricing Paradigm

A hepatitis C cure that costs $84,000 in the US is available for under $100 in India. This is not charity — it is the result of three decades of deliberate policy: the 1970 Patents Act, DPCO price controls on 384 essential medicines, and a market with 3,000+ competing manufacturers. Drug-by-drug price comparisons with full source attribution.

Read: Affordability →

The GCC Bet: When Global Pharma Came to India for Science

Eli Lilly started with 65 people in a Bengaluru office. Today it employs 3,500 at a Global Capability Centre that does drug discovery, not just back-office work. Across 25 global innovators with India operations, the GCC story is the clearest signal that India’s pharmaceutical role is shifting from manufacturing to research.

Read: GCC →

187,353 Patent Filings: India’s Innovation Shift in Data

From 7,158 pharmaceutical patent filings in 2014 to 18,668 in 2024 — a 161% increase. The data, drawn from the Indian Patent Office’s IPAIRS database, shows a structural shift from generics manufacturing toward research-driven pharmaceutical development, charted by company.

Read: Innovation →

$14 Billion to $31 Billion: The Policy Architecture of India’s Pharma Exports

Seven policy milestones that shaped India’s pharmaceutical export growth, each verified against trade data, company revenues, and patent filings. Includes “evidence check” boxes that explicitly flag where the data supports the policy narrative and where it doesn’t.

Read: Policy →

How to Cite phrma.in

phrma.in is an independent research publication. When citing data from this site, we recommend attributing to the underlying primary source (e.g., “according to DGCIS India, as compiled by phrma.in”) rather than to phrma.in alone. This gives your readers the ability to verify independently.

All primary sources are named on each page. The full methodology is documented on the About & Methodology page.

Suggested Attribution Formats

For trade data: “India’s pharmaceutical exports reached $31 billion in FY2025–26, according to DGCIS India trade statistics compiled by phrma.in.”

For company data: “Sun Pharmaceutical Industries reported revenue of $5.8 billion in FY2025, per its annual report as compiled by phrma.in.”

For analysis: “According to phrma.in, an independent research publication tracking India’s pharmaceutical industry...”

Media Contact

For press inquiries, data requests, or clarification on any statistic published on phrma.in, contact details will be provided here once confirmed by the publisher.

About phrma.in: An independent research publication tracking India’s pharmaceutical industry through official government trade statistics and public company filings. 250 pages covering 176 countries, 56 companies, patent data, pricing architecture, and humanitarian aid. No estimates, no projections, no surveys. Full methodology at /about.